Expanding Investigations Into Endogenous Reparative Pluripotent Muse Cells Through Clinical Application, Based on the Intravenous Drip of Donor-derived Muse Cells
Muse cells also have specific systems to modulate immunoreactions. For example, HLA-G is one of the factors expressed in fetal cells in placenta that strongly suppress immunological attack from maternal immune system. Thus, fetal cells are protected from maternal immunological attack. Since Muse cells also express HLA-G, allogenic Muse cells can escape from immunorejection after systemic administration to patients. Through various tests Dezawa's team found that the allogenic Muse cells appeared to have no harmful effects and remain in the tissue after repair for more than half a year, and should therefore prove safe for general use. 'As Muse cells need only be grown to create more of them, there is no need to work out how best to differentiate them in vitro,' she points out. As a result of their huge potential, Dezawa has teamed up with Life Sciences Institute Inc, a healthcare and medicine provider, to begin trials and, hopefully, distribution of the treatment.
The future of Muse cells is extremely promising. Human trials are beginning for their use in of cases acute myocardial infarction and stroke. The range of potential uses is almost limitless if these trials are successful. For Dezawa and her team this is culmination of many years of work, however, there is still much to find out. 'Muse cells are still a very interesting target from a biological point of view,' she confirms. 'We are now planning to expand our study of their biology in order to compare the endogenous reparative systems of human against those of lower animals such as amphibians and fishes.' Further foundational work such as this will continue to shed light on the clinical applications which Dezawa and her team will also remain heavily involved with.
Keywords: ACUTE MYOCARDIAL INFARCTION; ALLOGENIC MUSE CELLS; BONE MARROW; CONNECTIVE TISSUES; ENDOGENOUS REPARATIVE STEM CELLS; ENDOGENOUS REPARATIVE SYSTEMS; IMMUNOREJECTION; MODULATE IMMUNOREACTIONS; MULTILINEAGE-DIFFERENTIATING STRESS ENDURING CELLS; MUSE CELLS; NOVEL STEM CELL TYPE; PERIPHERAL BLOOD; REGENERATIVE MEDICINE; STROKE
Document Type: Research Article
Publication date: March 1, 2019
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites